Global OAB Treatment Market Growth (Status and Outlook) 2025-2031

Global OAB Treatment Market Growth (Status and Outlook) 2025-2031

The global OAB Treatment market size is predicted to grow from US$ 4969 million in 2025 to US$ 5441 million in 2031; it is expected to grow at a CAGR of 1.5% from 2025 to 2031.

Overactive bladder (OAB) is a common disease characterized by urinary urgency, often accompanied by frequent urination and nocturia, with or without urge urinary incontinence. This report focuses on the OAB treatment drug market, which is divided into: anticholinergic drugs, Mirabegron, Botox and others by drug type.

Overactive bladder (OAB) is a common disease, and the incidence of OAB shows an upward trend with age. With the continuous increase in the global elderly population, the number of elderly OAB patients has shown an upward trend year by year, which has attracted further attention from governments and the pharmaceutical treatment market. The OAB treatment drug market has great potential. The introduction of pharmaceutical industry policies, the policy changes and market environment, and the policy trends and future market development trends, although there are challenges, are actually evolving in a direction that is beneficial to innovative enterprises, which is conducive to promoting the long-term standardized development of the industry and providing good opportunities for OAB new drug companies with high-level R&D, production and quality management systems. It will be conducive to promoting the development of the OAB treatment drug industry. With the continuous advancement of technology and the innovation of new instruments, the surge in the number of new drugs discovered, the increase in government funds and the undeveloped emerging markets will further generate profitable markets, thereby promoting the market growth of OAB drugs. With the continuous increase in global healthcare infrastructure spending, the increase in per capita disposable income and the expansion of medical insurance coverage, residents' ability to pay for medical care has increased, driving the development of the OAB drug industry.

LPI (LP Information)' newest research report, the “OAB Treatment Industry Forecast” looks at past sales and reviews total world OAB Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected OAB Treatment sales for 2025 through 2031. With OAB Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world OAB Treatment industry.

This Insight Report provides a comprehensive analysis of the global OAB Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on OAB Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global OAB Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for OAB Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global OAB Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of OAB Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Anticholinergics
Mirabegron
Botox
Others

Segmentation by Application:
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Astellas Pharma
Pfizer
Teva
Johnson & Johnson
Kyorin Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.